A Phase 3 interventional study of BNT162b2 in SARS-CoV-2 Infection and COVID-19, sponsored by BioNTech SE. Completed at 21 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-12-23.
Sponsored by BioNTech SE · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 54 studies testing BNT162 Vaccine in COVID-19 — 4 open to participants now, 6 under way, 1 of them phase 3. BNT162 Vaccine · COVID-19.
Among the 54 studies testing BNT162 Vaccine in COVID-19, this one is the 23rd largest by enrollment, is one of 30 that started in 2021, is one of 18 in phase 3, and was the 13th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →4 of the 54 studies testing BNT162 Vaccine in COVID-19 are open now, in 6 countries. Recruiting first, the newest first:
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
Technical University of Munich · Sites in Austria, Belgium, Germany and 2 more countries
Ages 3 mo–4 mo · Healthy volunteers
PharmaJet, Inc. · Sites in United States
Ages 18–50 · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
54 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 24 · Phase 3 23 · Phase 4 11
First in 2020; this study’s year is marked. 30 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 629 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 575 across the 54 interventional studies. Of the 39 that completed or were terminated, 28 (72%) have results posted.
This tab as a report to print or save as PDF → With an account.
23 of 54 have an industry lead sponsor. The 10 most frequent:
BioNTech SE is the lead sponsor of 76 studies on the registry; 25 are open to participants now.
Of its 33 completed or terminated interventional studies of FDA-regulated products, 26 (79%) have results posted.
35 studies in COVID-19 by BioNTech SE: 2 open now, 2 under way, 1 of them phase 3. Of 31 finished, 25 (81%) have results posted.
Among the 35 studies in COVID-19 by BioNTech SE, this one is the 22nd largest by enrollment, is one of 10 that started in 2021, is one of 14 in phase 3, and was the 14th registered.
BioNTech SE’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing BNT162 Vaccine in COVID-19 that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07730450BioNTech SEA Study to Learn About a COVID-19 Vaccine in Healthy Adults 18 Through 64 Years of Age | 2027-08-20 |
| NCT06452654Technical University of MunichAnti-viral Action Against Type 1 Diabetes Autoimmunity | 2027-10 |
Add all 3 to your calendar (.ics) → With an account.
Among the 54 studies testing BNT162 Vaccine in COVID-19, from their registry updates:
Among BioNTech SE’s 35 in COVID-19:
This tab as a report to print or save as PDF → With an account.
This study will compare the safety and tolerability of lyophilized BNT162b2 presented in single dose vials to those of frozen-liquid BNT162b2 in multidose vials and determine whether the immune response is noninferior. Separately, the study will also describe the safety and immunogenicity of frozen-liquid BNT162b2 with lipid nanoparticle size at the upper end of specification and ready to use BNT162b2 (the immediate manufacturing precursor to the lyophilate). Additionally, the study will describe the safety and immunogenicity of an additional dose of frozen liquid BNT162b2 to participants who already received the 2-dose schedule of lyophilized BNT162b2.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: BNT162b2
Control for lyophilized SDV
Biological: BNT162b2
Biological: BNT162b2
Biological: BNT162b2
Additional vaccine dose, using the frozen-liquid formulation, offered to participants who originally received 2 doses of the lyophilized formulation of BNT162b2
Biological: BNT162b2
Intramuscular injection
Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2
GMTs of full-length S-binding IgG level for lyophilized formulation in SDVs and frozen-Liquid formulation in MDVs were reported in this outcome measure as geometric mean concentration (GMCs) in descriptive data section. GMC and 95 percent (%) confidence interval (CI) were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was calculated as ratios of GMCs of BNT162b2 30 mcg lyophilized SDV and frozen-liquid MDV. GMR are reported in the statistical analysis section.
Time frame: 1 Month after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 1
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 1 were reported.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 2 were reported.
Time frame: Within 7 days after Dose 2
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 2
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Dose 1 up to 1 Month after Dose 2 (for approximately 2 months)
Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Baseline (Before Dose 1 on Day 1)
Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2
GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2
GMTs of full-length S-binding IgG level for frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs were reported in this outcome measure as GMCs in descriptive data section. GMC and 95 % CI were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMR was calculated as ratios of GMCs of BNT162b2 30 mcg frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs. GMR are reported in the statistical analysis section.
Time frame: 1 Month after Dose 2
GMCs of Full-length S-binding IgG Levels at Baseline and 1 Month After Dose 2: Part 2
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Baseline (Before Dose 1 on Day 1), 1 Month after Dose 2
GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From Baseline (Before Dose 1 on Day 1) up to 1 Month after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 3 were reported.
Time frame: Within 7 days after Dose 3
Number of Participants With AEs and SAEs From Dose 3 to 1 Month After Dose 3
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
Time frame: Dose 3 up to 1 Month after Dose 3 (1 month)
GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3
GMFRs were defined as ratios of the geometric mean concentration of IgG from 1 month after Dose 3 to geometric mean concentration of IgG before Dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: From before Dose 3 to 1 Month after Dose 3
GMCs of Full-Length S-Binding IgG Levels at Baseline, 1 Month After Dose 2, Before Dose 3, and 1 Month After Dose 3
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
Time frame: Baseline, 1 Month after Dose 2, before Dose 3, and 1 Month after Dose 3
| Milestone | BNT162b2 Lyophilized Single Dose Vial (SDV): Part 1 | BNT162b2 Frozen-Liquid Multi Dose Vial (MDV): Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Started | 279 | 280 | 0 | 0 |
| Vaccinated at dose 1 | 279 | 280 | 0 | 0 |
| Vaccinated at dose 2 | 276 | 277 | 0 | 0 |
| Vaccination at dose 3 | 114 | 0 | 0 | 0 |
| Completed | 275 | 274 | 0 | 0 |
| Not completed | 4 | 6 | 0 | 0 |
| Withdrew: Adverse event | 1 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 2 | 2 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 1 | 2 | 0 | 0 |
| Milestone | BNT162b2 Lyophilized Single Dose Vial (SDV): Part 1 | BNT162b2 Frozen-Liquid Multi Dose Vial (MDV): Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Started | 0 | 0 | 35 | 35 |
| Vaccinated at dose 1 | 0 | 0 | 35 | 35 |
| Vaccinated at dose 2 | 0 | 0 | 35 | 35 |
| Completed | 0 | 0 | 33 | 34 |
| Not completed | 0 | 0 | 2 | 1 |
| Withdrew: Other | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 |
GMTs of full-length S-binding IgG level for lyophilized formulation in SDVs and frozen-Liquid formulation in MDVs were reported in this outcome measure as geometric mean concentration (GMCs) in descriptive data section. GMC and 95 percent (%) confidence interval (CI) were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. Geometric mean ratio (GMR) was calculated as ratios of GMCs of BNT162b2 30 mcg lyophilized SDV and frozen-liquid MDV. GMR are reported in the statistical analysis section.
| Unit per milliliter | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 |
|---|---|---|
| Geometric Mean Titers (GMTs) of Full-Length S-Binding IgG Concentrations of Lyophilized Formulation SDVs and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2 | 4796.8 (4414.1 to 5212.8) | 7031.6 (6393.6 to 7733.3) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.
| Percentage of participants | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Redness | 4.0 (2.0 to 7.0) | 5.0 (2.8 to 8.2) | 0 (0.0 to 10.0) | 2.9 (0.1 to 14.9) |
| Swelling | 3.6 (1.7 to 6.5) | 3.6 (1.7 to 6.5) | 0 (0.0 to 10.0) | 5.7 (0.7 to 19.2) |
| Pain at Injection Site | 78.1 (72.7 to 82.8) | 87.1 (82.6 to 90.8) | 85.7 (69.7 to 95.2) | 68.6 (50.7 to 83.1) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after each vaccination.
| Percentage of participants | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Redness | 3.6 (1.8 to 6.6) | 5.5 (3.1 to 8.9) | 0 (0.0 to 10.0) | 0 (0.0 to 10.0) |
| Swelling | 2.9 (1.3 to 5.7) | 3.3 (1.5 to 6.1) | 0 (0.0 to 10.0) | 8.6 (1.8 to 23.1) |
| Pain at Injection Site | 71.2 (65.4 to 76.5) | 80.3 (75.1 to 84.8) | 71.4 (53.7 to 85.4) | 62.9 (44.9 to 78.5) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 1 were reported.
| Percentage of participants | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Fever >=38.0 degree C | 0 (0.0 to 1.3) | 3.2 (1.5 to 6.0) | 0 (0.0 to 10.0) | 0 (0.0 to 10.0) |
| Fatigue | 46.4 (40.4 to 52.5) | 57.5 (51.5 to 63.4) | 54.3 (36.6 to 71.2) | 45.7 (28.8 to 63.4) |
| Headache | 31.3 (25.9 to 37.1) | 44.3 (38.4 to 50.3) | 37.1 (21.5 to 55.1) | 31.4 (16.9 to 49.3) |
| Chills | 8.6 (5.6 to 12.6) | 18.6 (14.2 to 23.6) | 8.6 (1.8 to 23.1) | 8.6 (1.8 to 23.1) |
| Vomiting | 2.9 (1.3 to 5.6) | 2.1 (0.8 to 4.6) | 5.7 (0.7 to 19.2) | 2.9 (0.1 to 14.9) |
| Diarrhea | 14.4 (10.5 to 19.1) | 13.9 (10.1 to 18.5) | 5.7 (0.7 to 19.2) | 11.4 (3.2 to 26.7) |
| New or worsened muscle pain | 16.5 (12.4 to 21.4) | 27.1 (22.0 to 32.8) | 11.4 (3.2 to 26.7) | 20.0 (8.4 to 36.9) |
| New or worsened joint pain | 7.9 (5.0 to 11.7) | 15.4 (11.3 to 20.1) | 11.4 (3.2 to 26.7) | 17.1 (6.6 to 33.6) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree C. Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 2 were reported.
| Percentage of participants | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| Fever >=38.0 degree C | 6.2 (3.7 to 9.7) | 12.4 (8.7 to 16.9) | 2.9 (0.1 to 14.9) | 5.7 (0.7 to 19.2) |
| Fatigue | 60.9 (54.9 to 66.8) | 75.2 (69.6 to 80.2) | 48.6 (31.4 to 66.0) | 60.0 (42.1 to 76.1) |
| Headache | 48.2 (42.1 to 54.3) | 61.7 (55.6 to 67.5) | 40.0 (23.9 to 57.9) | 40.0 (23.9 to 57.9) |
| Chills | 27.7 (22.5 to 33.4) | 46.4 (40.3 to 52.4) | 22.9 (10.4 to 40.1) | 17.1 (6.6 to 33.6) |
| Vomiting | 3.6 (1.8 to 6.6) | 2.2 (0.8 to 4.7) | 2.9 (0.1 to 14.9) | 0 (0.0 to 10.0) |
| Diarrhea | 12.8 (9.1 to 17.3) | 14.6 (10.6 to 19.3) | 8.6 (1.8 to 23.1) | 14.3 (4.8 to 30.3) |
| New or worsened muscle pain | 32.8 (27.3 to 38.8) | 43.1 (37.1 to 49.2) | 20.0 (8.4 to 36.9) | 37.1 (21.5 to 55.1) |
| New or worsened joint pain | 16.8 (12.6 to 21.8) | 32.1 (26.6 to 38.0) | 11.4 (3.2 to 26.7) | 28.6 (14.6 to 46.3) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Participants | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|---|---|
| AEs | 16 | 21 | 4 | 4 |
| SAEs | 0 | 0 | 0 | 0 |
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 |
|---|---|---|
| Geometric Mean Concentrations (GMCs) of Full-length S-binding IgG Levels at Baseline: Part 1 | 2.2 (1.8 to 2.6) | 2.2 (1.8 to 2.6) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 |
|---|---|---|
| Geometric Mean Fold Rises (GMFRs) in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 1 | 2189.0 (1841.6 to 2601.9) | 3194.0 (2665.8 to 3826.8) |
GMTs of full-length S-binding IgG level for frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs were reported in this outcome measure as GMCs in descriptive data section. GMC and 95 % CI were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ. GMR was calculated as ratios of GMCs of BNT162b2 30 mcg frozen liquid with LNP size at upper end of specification relative to frozen-liquid formulation in MDVs. GMR are reported in the statistical analysis section.
| Unit per milliliter | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|
| GMTs of Full-Length S-Binding IgG Concentrations of Frozen Liquid With LNP Size at Upper End of Specification and Frozen-Liquid Formulation in MDVs 1 Month After Dose 2 | 7773.3 (5758.5 to 10493.1) | 6839.9 (5242.9 to 8923.5) |
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|
| Baseline | 2.3 (1.3 to 4.3) | 3.3 (1.6 to 6.7) |
| 1 Month after Dose 2 | 7773.3 (5758.5 to 10493.1) | 6839.9 (5242.9 to 8923.5) |
GMFRs were defined as ratios of the geometric mean concentration of IgG at 1 month after Dose 2 to the geometric mean concentration of IgG at Baseline. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 |
|---|---|---|
| GMFRs in Full-length S-binding IgG Levels From Baseline to 1 Month After Dose 2: Part 2 | 3339.1 (1662.6 to 6706.4) | 2072.1 (987.5 to 4348.0) |
Local reactions were collected by the participant using an electronic diary. Local reactions included redness, swelling, and pain at injection site after Dose 3.
| Percentage of participants | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|
| Redness | 6.5 (2.7 to 13.0) |
| Swelling | 6.5 (2.7 to 13.0) |
| Pain at Injection Site | 70.1 (60.5 to 78.6) |
Systemic events were reported using an electronic diary. Fever was defined as temperature \>=38.0 degree Celsius (C). Systemic events including fever, fatigue, headache, chills, new or worsened muscle pain, new or worsened joint pain, vomiting, and diarrhea after Dose 3 were reported.
| Percentage of participants | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|
| Fever >=38.0 degree C | 8.4 (3.9 to 15.4) |
| Fatigue | 63.6 (53.7 to 72.6) |
| Headache | 52.3 (42.5 to 62.1) |
| Chills | 39.3 (30.0 to 49.2) |
| Vomiting | 2.8 (0.6 to 8.0) |
| Diarrhea | 13.1 (7.3 to 21.0) |
| New or worsened muscle pain | 29.0 (20.6 to 38.5) |
| New or worsened joint pain | 16.8 (10.3 to 25.3) |
| Use of antipyretic or pain medication | 35.5 (26.5 to 45.4) |
An AE was any untoward medical occurrence in a participant who received investigational product without regard to possibility of causal relationship. SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect or that was considered to be an important medical event. AEs included all non-SAEs and SAEs. Only AEs collected by non-systematic assessment (i.e. excluding local reactions and systemic events) were reported in this outcome measure.
| Participants | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|
| AEs | 10 |
| SAEs | 0 |
GMFRs were defined as ratios of the geometric mean concentration of IgG from 1 month after Dose 3 to geometric mean concentration of IgG before Dose 3. GMFRs were calculated by exponentiating the mean logarithm of fold rises and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Fold rise | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|
| GMFRs in Full-length S-binding IgG Levels From Before Dose 3 to 1 Month After Dose 3 | 16.0 (13.9 to 18.5) |
GMCs of full-length S-binding IgG levels were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student t distribution). Assay results below the LLOQ were set to 0.5\*LLOQ.
| Unit per milliliter | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|
| Baseline | 2.1 (1.6 to 2.7) |
| 1 Month after Dose 2 | 4612.2 (4065.7 to 5232.1) |
| Before Dose 3 | 874.4 (735.6 to 1039.4) |
| 1 Month after Dose 3 | 14006.7 (11902.7 to 16482.7) |
Collected over AEs and SAEs- For Part 1 and Part 2: Day 1 of Dose 1 up to 1 Month after Dose 2 (approximately2 months); Dose 3: From Dose 3 to 1 Month after Dose 3 (up to 1 month); Local reactions/systemic events (systematic collection): Within 7 days after each dose. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| BNT162b2 Lyophilized SDV: Part 1 | 0/279 (0%) | 0/279 (0%) | 262/279 (93.9%) |
| BNT162b2 Frozen-Liquid MDV: Part 1 | 0/280 (0%) | 0/280 (0%) | 274/280 (97.9%) |
| BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | 0/35 (0%) | 0/35 (0%) | 33/35 (94.3%) |
| BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 | 0/35 (0%) | 0/35 (0%) | 31/35 (88.6%) |
| BNT162b2 Frozen-Liquid MDV: Dose 3 | 0/114 (0%) | 0/114 (0%) | 87/114 (76.3%) |
| Event | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With Lipid Nanoparticle (LNP) Size: Part 2 | BNT162b2 Frozen-Liquid With Ready-to-use (RTU) Size: Part 2 | BNT162b2 Frozen-Liquid MDV: Dose 3 |
|---|---|---|---|---|---|
| Injection site pain (PAIN)General disorders | 240/279 | 261/280 | 31/35 | 28/35 | 75/114 |
| Fatigue (FATIGUE)General disorders | 199/279 | 233/280 | 24/35 | 24/35 | 68/114 |
| Headache (HEADACHE)Nervous system disorders | 162/279 | 198/280 | 18/35 | 19/35 | 56/114 |
| Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders | 116/279 | 153/280 | 9/35 | 16/35 | 31/114 |
| Chills (CHILLS)General disorders | 84/279 | 148/280 | 9/35 | 9/35 | 42/114 |
| Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders | 61/279 | 103/280 | 8/35 | 13/35 | 18/114 |
| Diarrhoea (DIARRHEA)Gastrointestinal disorders | 64/279 | 71/280 | 5/35 | 7/35 | 14/114 |
| Pyrexia (FEVER)General disorders | 17/279 | 41/280 | 1/35 | 2/35 | 9/114 |
| Injection site swelling (SWELLING)General disorders | 17/279 | 18/280 | 0/35 | 4/35 | 7/114 |
| Vomiting (VOMITING)Gastrointestinal disorders | 16/279 | 12/280 | 3/35 | 1/35 | 3/114 |
Safety population set included all randomized participants who received at least 1 dose of the study intervention.
| Age, Categorical(Participants) | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With LNP Size: Part 2 | BNT162b2 Frozen-Liquid With RTU Size: Part 2 | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 279 | 280 | 35 | 35 | 629 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With LNP Size: Part 2 | BNT162b2 Frozen-Liquid With RTU Size: Part 2 | Total |
|---|---|---|---|---|---|
| Female | 143 | 126 | 20 | 18 | 307 |
| Male | 136 | 154 | 15 | 17 | 322 |
| Ethnicity (NIH/OMB)(Participants) | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With LNP Size: Part 2 | BNT162b2 Frozen-Liquid With RTU Size: Part 2 | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 57 | 55 | 5 | 9 | 126 |
| Not Hispanic or Latino | 219 | 221 | 30 | 25 | 495 |
| Unknown or Not Reported | 3 | 4 | 0 | 1 | 8 |
| Race (NIH/OMB)(Participants) | BNT162b2 Lyophilized SDV: Part 1 | BNT162b2 Frozen-Liquid MDV: Part 1 | BNT162b2 Frozen-Liquid With LNP Size: Part 2 | BNT162b2 Frozen-Liquid With RTU Size: Part 2 | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 2 | 0 | 0 | 2 |
| Asian | 26 | 16 | 6 | 3 | 51 |
| Native Hawaiian or Other Pacific Islander | 3 | 2 | 0 | 0 | 5 |
| Black or African American | 19 | 34 | 2 | 3 | 58 |
| White | 228 | 220 | 24 | 28 | 500 |
| More than one race | 3 | 5 | 2 | 0 | 10 |
| Unknown or Not Reported | 0 | 1 | 1 | 1 | 3 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Apr 2021 to primary completion in Dec 2021, 8 months.
Results were first posted in Dec 2022, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 8 months is close to that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: BNT162 Vaccine